{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:46:57Z","timestamp":1793774817046,"version":"4.6.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.blre.2021.100809","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T11:50:54Z","timestamp":1614167454000},"page":"100809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Hypereosinophilic syndromes \u2013 An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment"],"prefix":"10.1016","volume":"49","author":[{"given":"Grzegorz","family":"Helbig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy D.","family":"Klion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2021.100809_bb0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related conditions","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2021.100809_bb0010","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100809_bb0015","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood.V83.10.2759.2759","article-title":"The idiopathic hypereosinophilic syndrome","volume":"83","author":"Weller","year":"1994","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100809_bb0020","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2021.100809_bb0025","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MD.0b013e3182a71eba","article-title":"The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia. New insights based on a survey of 44 cases","volume":"92","author":"Legrand","year":"2013","journal-title":"Medicine."},{"key":"10.1016\/j.blre.2021.100809_bb0030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MD.0000000000000088","article-title":"The lymphoid variant of hypereosinophilic syndrome. Study of 21 patients with CD3-CD4+ aberrant T-cell phenotype","volume":"93","author":"Lefevre","year":"2014","journal-title":"Medicine."},{"key":"10.1016\/j.blre.2021.100809_bb0035","article-title":"Symptom assessment in hypereosinophilic syndrome: toward development of a patient-reported tool","volume":"May 15","author":"Kovacs","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.blre.2021.100809_bb0040","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.iac.2015.05.003","article-title":"Eosinophilia in infectious diseases","volume":"35","author":"O\u2019Connell","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.blre.2021.100809_bb0045","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100809_bb0050","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100809_bb0055","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100809_bb0060","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/MPH.0000000000001446","article-title":"Myeloid neoplasm with eosinophilia and FIP1L1-PDGFRA rearrangement treated with imatinib mesylate: a pediatric case with long-term follow-up","volume":"41","author":"Srinivasan","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.blre.2021.100809_bb0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/hon.919","article-title":"Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript \u2013 results of a polish multicenter study","volume":"28","author":"Helbig","year":"2010","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.blre.2021.100809_bb0070","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/all.12843","article-title":"Clinical features predict responsiveness to imatinib in platelet-derived growth factor recetor-alpha-negative hypereosinophilic syndrome","volume":"71","author":"Khoury","year":"2016","journal-title":"Allergy."},{"key":"10.1016\/j.blre.2021.100809_bb0075","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1111\/bjh.16340","article-title":"Frequent false-negative FIP1L1-PDGFRA FISH analysis of bone marrow samples from clonal eosinophilia at diagnosis","volume":"188","author":"Olsson-Arvidsson","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100809_bb0080","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100809_bb0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2141.2007.06628.x","article-title":"Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukemia","volume":"138","author":"Curtis","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100809_bb0090","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.6004\/jnccn.2020.0042","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021, NCCN clinical practice guidelines in oncology","volume":"18","author":"Gerds","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.blre.2021.100809_bb0095","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","article-title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma","volume":"21","author":"Metzgeroth","year":"2007","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2021.100809_bb0100","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/blood-2013-07-516500","article-title":"Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement","volume":"122","author":"Jain","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100809_bb0105","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2007.05.024","article-title":"KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1-PDGFRA-associated chronic eosinophilic leukemia are distinct entities","volume":"120","author":"Maric","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2021.100809_bb0110","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00277-017-3067-x","article-title":"Imatinib in myeloid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase","volume":"96","author":"Jawhar","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2021.100809_bb0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-0609.2012.01799.x","article-title":"Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement","volume":"89","author":"Arefi","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2021.100809_bb0120","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jamadermatol.2016.3175","article-title":"Novel chromosome 5 inversion associated with PDGFRB rearrangement in hypereosinophilic syndrome","volume":"152","author":"Saultz","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.blre.2021.100809_bb0125","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.humpath.2009.11.003","article-title":"8p11 myeloproliferative syndrome: a review","volume":"41","author":"Jackson","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.blre.2021.100809_bb0130","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1182\/bloodadvances.2020002308","article-title":"Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia","volume":"4","author":"Kasbekar","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2021.100809_bb0135","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/bjh.12963","article-title":"Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?","volume":"166","author":"Bain","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100809_bb0140","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3109\/10428190309178786","article-title":"Eosinophilic variant of chronic myeloid leukemia with vascular complications","volume":"44","author":"Gotlib","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2021.100809_bb0145","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/ajh.24075","article-title":"KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknoiwn significance","volume":"90","author":"Schwaab","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100809_bb0150","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41375-018-0342-3","article-title":"Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia","volume":"33","author":"Cross","year":"2019","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2021.100809_bb0155","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1182\/blood.2019001385","article-title":"JAK2ex13inDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera","volume":"134","author":"Patel","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100809_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25811","article-title":"WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL-NOS): a contemporary series from the Mayo Clinic","author":"Morsia","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100809_bb0165","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ajh.23193","article-title":"Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation","volume":"87","author":"Helbig","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100809_bb0170","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1182\/blood.V87.4.1416.bloodjournal8741416","article-title":"CD4+ T-cell population able to secrete large amounts of interleukin-5","volume":"87","author":"Brugnoni","year":"1996","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100809_bb0175","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3109\/10428194.2014.976823","article-title":"Lymphocytic variant hypereosinophilic syndrome progressing to angioimmunoblastic T-cell lymphoma","volume":"56","author":"Roufosse","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2021.100809_bb0180","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.iac.2007.07.002","article-title":"Lymphocytic variant hypereosinophilic syndromes","volume":"27","author":"Roufosse","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.blre.2021.100809_bb0185","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3324\/haematol.2008.005447","article-title":"T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome","volume":"94","author":"Helbig","year":"2009","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100809_bb0190","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2015-06-654277","article-title":"Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic hypereosinophilic syndrome","volume":"126","author":"Walker","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100809_bb0195","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2021.100809_bb0200","article-title":"Idiopathic hypereosinophilia is clonal disorder? Clonality identified by targeted sequencing","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2021.100809_bb0205","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1080\/10428194.2018.1564825","article-title":"Evidence of clonality in cases with hypereosinophilia of undetermined significance","volume":"60","author":"Pohlkamp","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2021.100809_bb0210","doi-asserted-by":"crossref","first-page":"692","DOI":"10.20452\/pamw.3061","article-title":"Cardiovascular dysfunction as a common cause of mortality in hypereosinophilic syndrome","volume":"125","author":"Helbig","year":"2015","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.blre.2021.100809_bb0215","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaci.2013.06.037","article-title":"Marked and persistent eosinophilia in the absence of clinical manifestations","volume":"133","author":"Chen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2021.100809_bb0220","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s12032-013-0815-1","article-title":"Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance","volume":"31","author":"Helbig","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.blre.2021.100809_bb0225","first-page":"255","article-title":"Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group","volume":"130","author":"Helbig","year":"2020","journal-title":"Pol Arch Int Med"},{"key":"10.1016\/j.blre.2021.100809_bb0230","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2008.07033.x","article-title":"A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients","volume":"141","author":"Helbig","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100809_bb0235","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3109\/10428194.2015.1065983","article-title":"Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript","volume":"3","author":"Helbig","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2021.100809_bb0240","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/bloodadvances.2019001111","article-title":"Treatment-free remission in FIP1L1-PDGFRA-positive myeloid\/lymphoid neoplasms with eosinophilia after imatinib discontinuation","volume":"11","author":"Metzgeroth","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2021.100809_bb0245","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25945","article-title":"Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: data from 151 patients","author":"Rohmer","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100809_bb0250","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/leu.2012.8","article-title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases","volume":"26","author":"Lierman","year":"2012","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2021.100809_bb0255","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/leu.2011.181","article-title":"Limited clinical activity of nilotinib, and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation","volume":"26","author":"Metzgeroth","year":"2012","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2021.100809_bb0260","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2014-02-555607","article-title":"Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100809_bb0265","doi-asserted-by":"crossref","first-page":"14479","DOI":"10.1073\/pnas.0404438101","article-title":"PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2021.100809_bb0270","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2015.136","article-title":"Clinical activity of ponatinib in a patient with FGFR1-rarranged mixed phenotype acute leukemia","volume":"30","author":"Khodadoust","year":"2016","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2021.100809_bb0275","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood-2018-99-110388","article-title":"Interim results from Fight-203, a phase 2, open-label, multicenter study evaluating the efficacy and safety of pemigatinib (INCB054828) in patients with myeloid\/lymphoid neoplasms with rearrangement of fibroblast growth factor receptor 1","volume":"132","author":"Verstovsek","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100809_bb0280","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.V126.23.2812.2812","article-title":"Limited efficacy of ponatinib in myeloproliferative neoplasms associated with FGFR1 fusion genes","volume":"126","author":"Kreil","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100809_bb0285","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00277-014-2221-y","article-title":"Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-ABL2 fusion genes","volume":"94","author":"Schwaab","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2021.100809_bb0290","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-015-2451-7","article-title":"Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene","volume":"94","author":"Rumi","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2021.100809_bb0295","doi-asserted-by":"crossref","unstructured":"Helbig G, Wi\u015bniewska-Pi\u0105ty, Francuz T, Dziaczkowska-Suszek J, Kyrcz-Krzemie\u0144 S. Diversity of clinical manifestations and response to corticosteroids for idiopathic hypereosinophilic syndrome: retrospective study of 33 patients. Leuk Lymphoma 2013; 54: 807\u2013811.","DOI":"10.3109\/10428194.2012.731602"},{"key":"10.1016\/j.blre.2021.100809_bb0300","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaip.2017.06.006","article-title":"Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids","volume":"6","author":"Khoury","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.blre.2021.100809_bb0305","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/cea.13509","article-title":"Mechanisms of glucocorticoid resistance in hypereosinophilic syndrome","volume":"49","author":"Stokes","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.blre.2021.100809_bb0310","first-page":"383","article-title":"Heterogeneity of human eosinophil glucocorticoid receptor expression in eosinophilic patients: absence of detectable receptor correlates with resistance to corticotherapy","volume":"78","author":"Prin","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.blre.2021.100809_bb0315","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/1744666X.2018.1425142","article-title":"Imatinib for the treatment of hypereosinophilic syndrome","volume":"14","author":"Helbig","year":"2018","journal-title":"Exp Rev Clin Immunol"},{"key":"10.1016\/j.blre.2021.100809_bb0320","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Mepolizumab HES study group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100809_bb0325","first-page":"461","volume":"131","author":"Roufosse","year":"2013","journal-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes"},{"key":"10.1016\/j.blre.2021.100809_bb0330","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jaip.2018.04.033","article-title":"Long-term clinical outcome of high-dose mepolizumab treatment in hypereosinophilic syndrome","volume":"6","author":"Kuang","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.blre.2021.100809_bb0335","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100809_bb0340","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100809_bb0345","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11899-018-0448-8","article-title":"Diagnosis and novel approaches to the treatment of hypereosinophilic syndromes","volume":"13","author":"Dispenza","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.blre.2021.100809_bb0350","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2141.2002.03771.x","article-title":"Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome","volume":"119","author":"Ueno","year":"2002","journal-title":"Br J Haematol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:26:29Z","timestamp":1759436789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X21000151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":70,"alternative-id":["S0268960X21000151"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2021.100809","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypereosinophilic syndromes \u2013 An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2021.100809","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100809"}}